Stereotaxis Appoints William C. Mills III to Chief Executive Officer

Stereotaxis Appoints William C. Mills III to Chief Executive Officer

ST. LOUIS, Feb. 14, 2014 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (Nasdaq:STXS)
announced today that its board of directors has appointed Chairman William C.
Mills III to Chief Executive Officer, effective February 12, 2014. Mr. Mills
has been serving as interim CEO since April 2013.

"Stereotaxis is now poised to build on our history of product innovation that
can result in major advances in the delivery of patient cardiac therapies,"
said Fred A. Middleton, Director. "We believe Bill is the right person to lead
these initiatives during the next phase of our Company's development."

"As Chairman of Stereotaxis, I am very mindful of our potential as a leading
innovator and provider of clinically validated robotic technology in the
expanding global market for complex cardiac electrophysiology (EP) procedures,
a market that is trending towards automation," said William Mills, Stereotaxis
Board Chairman and Chief Executive Officer. "With the substantial recent
progress we have made to strengthen the Company's financial position, we are
increasingly focused on furthering our product innovation to improve patient
outcomes, and I am very excited about the growth opportunities that we see
ahead."

Mr. Mills has served on the Stereotaxis Board of Directors since June 2000 and
was elected Chairman in May 2012. He has more than 30 years experience as a
venture capitalist with an emphasis on science-based medicine and medical
technology. Mr. Mills currently serves as a director on a number of venture
capital, corporate and advisory boards, in addition to his role with
Stereotaxis. He holds graduate degrees in Chemistry and in Management from MIT
and an A.B. in Chemistry from Princeton University.

About Stereotaxis

Stereotaxis is a healthcare technology and innovation leader in the
development of robotic cardiology instrument navigation systems designed to
enhance the treatment of arrhythmias and coronary disease, as well as
information management solutions for the interventional lab. With over 100
patents for use in a hospital's interventional surgical suite, Stereotaxis
helps physicians around the world provide unsurpassed patient care with
robotic precision and safety, improved lab efficiency and productivity, and
enhanced collaboration of life-saving information. Stereotaxis' core Epoch™
Solution includes the Niobe® ES Remote Magnetic Navigation system, the
Odyssey® portfolio of lab optimization, networking and patient information
management systems and the Vdrive™ Robotic Mechanical Navigation system and
consumables.

The core components of Stereotaxis systems have received regulatory clearance
in the U.S., Europe, Canada and elsewhere. The V-Sono™ ICE catheter
manipulator has received U.S. clearance, and the V-Loop™ circular catheter
manipulator will soon be submitted for review by the U.S. Food and Drug
Administration. For more information, please visit www.stereotaxis.com

This press release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate," "project,"
"expect" or similar expressions. Forward-looking statements inherently involve
risks and uncertainties that could cause actual results to differ materially
from the forward-looking statements. Factors that would cause or contribute to
such differences include, but are not limited to, the Company's ability to
raise additional capital on a timely basis and on terms that are acceptable,
its ability to continue to manage expenses and cash burn rate at sustainable
levels, its ability to continue to work with lenders to extend, repay or
refinance indebtedness on acceptable terms, continued acceptance of the
Company's products in the marketplace, the effect of global economic
conditions on the ability and willingness of customers to purchase its systems
and the timing of such purchases, the outcome of various shareholder
litigation filed against Stereotaxis, competitive factors, changes resulting
from the recently enacted healthcare reform in the U.S., including changes in
government reimbursement procedures, dependence upon third-party vendors,
timing of regulatory approvals, and other risks discussed in the Company's
periodic and other filings with the Securities and Exchange Commission. By
making these forward-looking statements, the Company undertakes no obligation
to update these statements for revisions or changes after the date of this
release. There can be no assurance that the Company will recognize revenue
related to its purchase orders and other commitments in any particular period
or at all because some of these purchase orders and other commitments are
subject to contingencies that are outside of the Company's control. In
addition, these orders and commitments may be revised, modified, delayed or
canceled, either by their express terms, as a result of negotiations, or by
overall project changes or delays.

CONTACT: Company Contact:
         Marty Stammer
         Chief Financial Officer
         314-678-6155
        
         Investor Contact:
         Todd Kehrli / Jim Byers
         MKR Group, Inc.
         323-468-2300
         stxs@mkr-group.com
 
Press spacebar to pause and continue. Press esc to stop.